(0.00%) 5 478.75 points
(-0.01%) 38 814 points
(0.04%) 19 930 points
(0.30%) $80.57
(0.79%) $2.81
(0.16%) $2 332.80
(-0.24%) $29.32
(-0.01%) $970.80
(0.03%) $0.932
(-0.11%) $10.64
(0.09%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases...
Stats | |
---|---|
Šios dienos apimtis | 2.21M |
Vidutinė apimtis | 1.21M |
Rinkos kapitalizacija | 451.87M |
EPS | $-0.510 ( Q1 | 2024-05-15 ) |
Kita pelno data | ( $-0.550 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.47 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0550 (0.59%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-03 | Bollard Catherine | Buy | 22 000 | Stock Option (Right to Buy) |
2024-06-03 | Simon Mark | Buy | 22 000 | Stock Option (Right to Buy) |
2024-06-03 | Henriques Richard C Jr | Buy | 22 000 | Stock Option (Right to Buy) |
2024-06-03 | Brun Scott C. | Buy | 22 000 | Stock Option (Right to Buy) |
2024-06-03 | Tomasello Shawn | Buy | 22 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
83.05 |
Last 97 transactions |
Buy: 4 904 600 | Sell: 1 671 054 |
Tūris Koreliacija
Cabaletta Bio Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
DLHC | 0.953 |
MPAA | 0.95 |
APVO | 0.945 |
MBIO | 0.941 |
SHLS | 0.938 |
RPTX | 0.937 |
AZTA | 0.933 |
QLGN | 0.93 |
DMRC | 0.93 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
JAN | -0.929 |
GERN | -0.926 |
VCTR | -0.923 |
PPTA | -0.917 |
GDST | -0.916 |
PPC | -0.915 |
IGLD | -0.915 |
RZLT | -0.915 |
AEYE | -0.911 |
GRIN | -0.91 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Cabaletta Bio Inc Koreliacija - Valiuta/Žaliavos
Cabaletta Bio Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-1.43M (0.00 %) |
EPS: | $-1.650 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-1.43M (0.00 %) |
EPS: | $-1.650 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-3.68M (0.00 %) |
EPS: | $-1.770 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.15 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.